CY1109356T1 - Θειολακτονες ως αναστολεις της νααladασης - Google Patents

Θειολακτονες ως αναστολεις της νααladασης

Info

Publication number
CY1109356T1
CY1109356T1 CY20091100904T CY091100904T CY1109356T1 CY 1109356 T1 CY1109356 T1 CY 1109356T1 CY 20091100904 T CY20091100904 T CY 20091100904T CY 091100904 T CY091100904 T CY 091100904T CY 1109356 T1 CY1109356 T1 CY 1109356T1
Authority
CY
Cyprus
Prior art keywords
compounds
activity
thiolakes
naladasis
analysis
Prior art date
Application number
CY20091100904T
Other languages
English (en)
Inventor
Takashi Tsukamoto
Barbara S Slusher
Original Assignee
Eisai Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc. filed Critical Eisai Inc.
Publication of CY1109356T1 publication Critical patent/CY1109356T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Αυτή η εφεύρεση παρέχει νέες ενώσεις, φαρμακευτικές συνθέσεις και διαγνωστικά κιτς που περιλαμβάνουν τέτοιες ενώσεις, και μεθόδους για τη χρήση τέτοιων ενώσεων για αναστολή της δραστηριότητας του ενζύμου της ΝΑΑLADάσης, την ανίχνευση των ασθενειών όπου τα επίπεδα της ΝΑΑLADάσης αλλοιώνονται, την αναστολή της αγγειογένεσης, την επίδραση μίας δραστηριότητας TGF-8 ή μίας νευρωνικής δραστηριότητας, και την θεραπεία μίας μη φυσιολογικής γλουταμίνης, μίας ψυχαναγκαστικής διαταραχής, της νευροπάθειας, του πόνου, μίας νόσου του προστάτη, του καρκίνου, της νόσου του Huntington, του διαβήτη, μίας διαταραχής του αμφιβληστροειδούς ή του γλαυκώματος.
CY20091100904T 2003-03-03 2009-08-28 Θειολακτονες ως αναστολεις της νααladασης CY1109356T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45064803P 2003-03-03 2003-03-03
EP04716834A EP1599461B1 (en) 2003-03-03 2004-03-03 THIOLACTONES AS NAALADase INHIBITORS

Publications (1)

Publication Number Publication Date
CY1109356T1 true CY1109356T1 (el) 2014-07-02

Family

ID=32962505

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100904T CY1109356T1 (el) 2003-03-03 2009-08-28 Θειολακτονες ως αναστολεις της νααladασης

Country Status (15)

Country Link
US (4) US7125907B2 (el)
EP (2) EP1988088A1 (el)
JP (1) JP4773951B2 (el)
AT (1) ATE433445T1 (el)
AU (1) AU2004217969B2 (el)
CA (1) CA2518234C (el)
CY (1) CY1109356T1 (el)
DE (1) DE602004021476D1 (el)
DK (1) DK1599461T3 (el)
ES (1) ES2326083T3 (el)
MX (1) MXPA05009492A (el)
PL (1) PL1599461T3 (el)
PT (1) PT1599461E (el)
SI (1) SI1599461T1 (el)
WO (1) WO2004078742A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4773951B2 (ja) * 2003-03-03 2011-09-14 エーザイ インコーポレーテッド チオラクトン
WO2008094664A1 (en) * 2007-01-31 2008-08-07 Adam Heller Methods and compositions for the treatment of pain
WO2017029399A1 (en) 2015-08-20 2017-02-23 Universität Zu Köln Pain tracking by pet-imaging (pain-trap)
WO2021155167A1 (en) * 2020-01-31 2021-08-05 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239636A (en) 1978-10-23 1980-12-16 Exxon Research & Engineering Co. Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions
JPH0532659A (ja) * 1991-08-01 1993-02-09 Tsumura & Co 糖尿病治療剤
GB9218810D0 (en) 1992-09-04 1992-10-21 Univ Birmingham Antiviral pyrimidine nucleosides
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
GB9602721D0 (en) 1996-02-09 1996-04-10 Pharmacia Spa Biologically active ureido derivatives useful in the treatment of multiple sclerosis
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
JP2002515040A (ja) 1996-06-17 2002-05-21 ギルフォード・ファーマシューティカルズ・インコーポレイテッド Ｎａａｌａｄアーゼ阻害剤を用いる癌治療方法
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US6025345A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US6071965A (en) 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
GB9615202D0 (en) 1996-07-19 1996-09-04 Smithkline Beecham Plc Pharmaceuticals
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6121252A (en) 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
US6265609B1 (en) * 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) * 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6458775B1 (en) * 1998-07-06 2002-10-01 Guilford Pharmaceutical Inc. NAALADase inhibitors useful as pharmaceutical compounds and compositions
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
ATE298343T1 (de) * 1999-04-28 2005-07-15 Univ Georgetown Ligande für metabotropische glutamat-rezeptoren
US6228888B1 (en) 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US6348464B1 (en) 1999-11-12 2002-02-19 Guilford Pharmaceuticals, Inc. Pyrrolecarbonylimino derivatives as naaladase inhibitors
WO2001091738A2 (en) 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating amyotrophic lateral sclerosis
WO2001092273A2 (en) 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
EP1292601A2 (en) 2000-05-30 2003-03-19 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating retinal disorders and glaucoma
US7651699B2 (en) * 2001-01-08 2010-01-26 Pathway Intermediates Limited Autoinducer compounds and their uses
FR2819253B1 (fr) * 2001-01-11 2004-12-03 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002057222A2 (en) * 2001-01-17 2002-07-25 Guilford Pharmaceuticals Inc. Thiol-based naaladase inhibitors
CA2446740A1 (en) 2001-05-11 2002-11-21 Guilford Pharmaceuticals Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
AU2002310202B2 (en) * 2001-05-30 2008-05-15 Eisai Inc. Thiolalkyl benzoic acid derivatives
WO2003057154A2 (en) 2001-12-28 2003-07-17 Guildford Pharmaceuticals Inc. Naaladase inhibitors for treating huntington's disease
JP4773951B2 (ja) 2003-03-03 2011-09-14 エーザイ インコーポレーテッド チオラクトン
WO2004078180A2 (en) 2003-03-03 2004-09-16 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance

Also Published As

Publication number Publication date
US7125907B2 (en) 2006-10-24
US7553866B2 (en) 2009-06-30
US20080004334A1 (en) 2008-01-03
PL1599461T3 (pl) 2009-10-30
WO2004078742A1 (en) 2004-09-16
EP1599461B1 (en) 2009-06-10
US20070037798A1 (en) 2007-02-15
MXPA05009492A (es) 2005-12-14
SI1599461T1 (sl) 2009-10-31
JP2006519858A (ja) 2006-08-31
DK1599461T3 (da) 2009-08-17
EP1988088A1 (en) 2008-11-05
US7968593B2 (en) 2011-06-28
US20100048667A1 (en) 2010-02-25
AU2004217969A1 (en) 2004-09-16
CA2518234A1 (en) 2004-09-16
EP1599461A1 (en) 2005-11-30
US20050004203A1 (en) 2005-01-06
AU2004217969B2 (en) 2011-03-03
PT1599461E (pt) 2009-07-20
DE602004021476D1 (de) 2009-07-23
ATE433445T1 (de) 2009-06-15
JP4773951B2 (ja) 2011-09-14
CA2518234C (en) 2012-11-13
ES2326083T3 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
CY1108893T1 (el) Παραγωγα θειοαλκυλ βενζοϊκου οξεος
WO2003057670A3 (en) Indoles as naaladase inhibitors
WO2002057222A3 (en) Thiol-based naaladase inhibitors
WO2001092273A3 (en) Benzenedicarboxylic acid derivatives
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
WO2005025511A3 (en) Potassium channel mediated delivery of agents through the blood-brain barrier
BRPI0407910A (pt) usos de compostos para prevenção, tratamento ou diagnóstico, em um indivìduo, de um distúrbio de agregação de proteìna
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2003065006A3 (en) Methods and compositions for treating cancer
CY1109356T1 (el) Θειολακτονες ως αναστολεις της νααladασης
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
DE69927502D1 (de) Naaladase-hemmer anwendbar als pharmazeutische verbindungen und zusammensetzungen
MXPA03010328A (es) Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
DE60037126D1 (de) POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE
WO2003070883A3 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2003073983A3 (en) Methods and compositions in treating pain using diacylglycerol kinase epsilon
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
WO2003065871A3 (en) Methods and compositions for treating hematological disorders
WO2002086084A3 (en) Sequence characteristics of bladder cancer
ATE404677T1 (de) Behandlungsverfahren unter verwendung von 17906 und dessen anwendungen
WO2003053364A3 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
WO2003039342A3 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
WO2003045229A3 (en) Methods and compositions for treating cancer
WO2003039475A8 (en) Methods of identifying and using modulators of fractalkine receptor